Clinical Trials in Rimouski, Canada
3 recruiting
Showing 1–20 of 20 trials
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more
AstraZeneca1,850 enrolled60 locationsNCT06465810
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled225 locationsNCT06617325
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled288 locationsNCT06393374
Recruiting
Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Merck Sharp & Dohme LLC1,200 enrolled196 locationsNCT06136559
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled205 locationsNCT06801834
Recruiting
Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled289 locationsNCT07207811
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled184 locationsNCT06646276
Recruiting
Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).
Resolution of InflammationReduction of Cell Proliferation
SCF Pharma200 enrolled1 locationNCT05161702
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche600 enrolled217 locationsNCT06793215
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled258 locationsNCT06312176
Recruiting
Phase 1
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Patients With Non-small-cell Lung Cancer
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 3
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Peripheral Arterial DiseaseInflammationAtherosclerosis of Extremities
Population Health Research Institute6,150 enrolled70 locationsNCT04774159
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-small Cell Lung Cancer
AstraZeneca675 enrolled281 locationsNCT06357533
Recruiting
Phase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Novartis Pharmaceuticals550 enrolled127 locationsNCT06133972
Recruiting
Phase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
Acute Coronary Syndrome
DalCor Pharmaceuticals2,000 enrolled223 locationsNCT05918861
Recruiting
Phase 4
Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).
cognitive healthBrain Fog
Samuel Fortin48 enrolled2 locationsNCT06695910
Recruiting
Not Applicable
Glyceryl Eicosapentaenoate Based Topic Products As an Irritant-free Cream and Serum for Hydration of Sensitive Skin
Skin Dryness
SCF Pharma33 enrolled1 locationNCT06219213
Recruiting
Not Applicable
Omega-3 Monoglyceride Based Topic Products as Skin Prebiotics for Eczema
Eczema
SCF Pharma16 enrolled1 locationNCT06155513